Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for thrombocytopenia before TACE in hepatocellular carcinoma
ChiCTR2500095567Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in Thrombocytopenia and hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Platelet count at day 15. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopeniahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500095567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095567.